youtube_live
Q2 2027 earnings • released • Revenue beat +1.47%
See resultschevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
¥4,590.00
arrow_upward
+4.32%(+190.00) 1D
Nov 18, 10:47:16 AM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
¥4,455
High
¥4,615
Low
¥4,370
Mkt. cap
213.63B
Avg. vol.
97.32K
Volume
173.50K
Dividend
2.72%
Quarterly dividend
¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
17.01
52-wk high
¥5,040
52-wk low
¥3,500
EPS
¥270
Shares outstanding
46.72M
No. of employees
2K
Open
¥4,455
High
¥4,615
Low
¥4,370
Mkt. cap
213.63B
Avg. vol.
97.32K
Volume
173.50K
Dividend
2.72%
Quarterly dividend
¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
17.01
52-wk high
¥5,040
52-wk low
¥3,500
EPS
¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
BigGo Finance
·
3 hours ago
New York Stocks Slip a Day Before Nvidia Earnings; S&P 500, Nasdaq Fall for Fourth Straight Session
TradingView
·
1 hour ago
S&P 500, Dow, Nasdaq Futures Power Ahead On Nvidia Outlook Beat — NVDA, TSLA, ANT In Focus
ChartMill
·
3 hours ago
S&P 500 After-Hours Gainers for Nov. 17, 2026
Traders Union
·
47 minutes ago
S&P 500 rises 10 percent amid challenging backdrop, Nate Geraci notes
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp